1. Home
  2. SPRO vs DERM Comparison

SPRO vs DERM Comparison

Compare SPRO & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • DERM
  • Stock Information
  • Founded
  • SPRO 2013
  • DERM 2014
  • Country
  • SPRO United States
  • DERM United States
  • Employees
  • SPRO N/A
  • DERM N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • DERM Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPRO Health Care
  • DERM Health Care
  • Exchange
  • SPRO Nasdaq
  • DERM Nasdaq
  • Market Cap
  • SPRO 164.4M
  • DERM 181.0M
  • IPO Year
  • SPRO 2017
  • DERM 2021
  • Fundamental
  • Price
  • SPRO $2.91
  • DERM $7.10
  • Analyst Decision
  • SPRO Buy
  • DERM Strong Buy
  • Analyst Count
  • SPRO 4
  • DERM 2
  • Target Price
  • SPRO $5.00
  • DERM $10.00
  • AVG Volume (30 Days)
  • SPRO 1.6M
  • DERM 178.0K
  • Earning Date
  • SPRO 08-04-2025
  • DERM 08-11-2025
  • Dividend Yield
  • SPRO N/A
  • DERM N/A
  • EPS Growth
  • SPRO N/A
  • DERM N/A
  • EPS
  • SPRO N/A
  • DERM N/A
  • Revenue
  • SPRO $44,584,000.00
  • DERM $56,243,000.00
  • Revenue This Year
  • SPRO N/A
  • DERM $28.99
  • Revenue Next Year
  • SPRO N/A
  • DERM $52.61
  • P/E Ratio
  • SPRO N/A
  • DERM N/A
  • Revenue Growth
  • SPRO N/A
  • DERM N/A
  • 52 Week Low
  • SPRO $0.51
  • DERM $3.54
  • 52 Week High
  • SPRO $3.09
  • DERM $8.25
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 71.62
  • DERM 52.70
  • Support Level
  • SPRO $2.79
  • DERM $6.63
  • Resistance Level
  • SPRO $3.03
  • DERM $7.28
  • Average True Range (ATR)
  • SPRO 0.12
  • DERM 0.38
  • MACD
  • SPRO -0.08
  • DERM 0.03
  • Stochastic Oscillator
  • SPRO 43.75
  • DERM 83.02

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About DERM Journey Medical Corporation

Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.

Share on Social Networks: